[{"orgOrder":0,"company":"Biotheus","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biotheus \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"Biotheus \/ BioNTech"},{"orgOrder":0,"company":"Biotheus","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"PM8002","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biotheus","amount2":1.0600000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.0600000000000001,"dosageForm":"Infusion","sponsorNew":"Biotheus \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Biotheus \/ BioNTech"},{"orgOrder":0,"company":"Biotheus","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"HS-20117","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biotheus \/ Hansoh Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Biotheus \/ Hansoh Pharma"},{"orgOrder":0,"company":"Biotheus","sponsor":"ImmunoPrecise","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"TATX-20","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Biotheus \/ Biotheus","highestDevelopmentStatusID":"14","companyTruncated":"Biotheus \/ Biotheus"}]

Find Clinical Drug Pipeline Developments & Deals by Biotheus

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Biotheus will obtain the rights to evaluate the suitability of Talem’s AI-enhanced TATX-20 candidate for the development of novel bispecific antibodies for the treatment of hypoxic solid tumors.

                          Brand Name : TATX-20

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 02, 2024

                          Lead Product(s) : TATX-20

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : ImmunoPrecise

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Through the partnership, Biotheus will grant Hansoh Pharma a license to use the lead product PM1080 (HS-20117) for EGFR/c-MET expressing neoplasms and including Non-Small-Cell Lung Carcinoma.

                          Brand Name : PM1080

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 15, 2024

                          Lead Product(s) : HS-20117

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Hansoh Pharma

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : BioNTech will be developing, manufacturing and commercializing PM8002, a bispecific antibody candidate being evaluated in patients with advanced solid tumors, globally ex-Greater China, whereas Biotheus retains the rights to exploit PM8002 in Greater Chi...

                          Brand Name : PM8002

                          Molecule Type : Large molecule

                          Upfront Cash : $55.0 million

                          November 07, 2023

                          Lead Product(s) : PM8002

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : BioNTech

                          Deal Size : $1,055.0 million

                          Deal Type : Licensing Agreement

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the terms of the agreement, Biotheus will grant BioNTech worldwide, exclusive options to a preclinical-stage bispecific antibody and a clinical-stage monoclonal antibody for cancer therapy.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          July 19, 2023

                          Lead Product(s) : Bispecific Antibody

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : BioNTech

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank